Fatigue in Multiple Sclerosis
8
2
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
25%
2 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis
Non-invasive Brain Stimulation in Multiple Sclerosis Fatigue
MS Fatigue and tDCS on Fatigue in Multiple Sclerosis
Sexual Dysfunction in Women With Multiple Sclerosis (MS)
Testing the Effects of Methylphenidate on Multiple Sclerosis
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis